FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384207941> ?p ?o ?g. }

• W4384207941 endingPage "T707" @default.
• W4384207941 startingPage "T680" @default.
• W4384207941 abstract "La vía JAK/STAT (Janus Kinase/Signal Transducer and Activator of Transcription) es esencial en la señalización final de una gran mayoría de interleucinas (IL) fundamentales en la patogénesis de la dermatitis atópica (DA). El bloqueo transversal que consiguen los inhibidores de JAK a través de la inhibición intermitente de las acciones de múltiples citocinas, permite modular la inflamación Th2, la disfunción de barrera epidérmica y la señalización del prurito. Sin embargo, esa inhibición amplia también puede asociarse con una mayor variedad de efectos adversos. En este artículo se revisan los inhibidores de JAK recientemente aprobados en DA - baricitinib, upadacitinib y abrocitinib - así como otros emergentes o en desarrollo como gusacitinib, delgocitinib, ruxolitinib, brepocitinib, tofacitinib y cerdulatinib. El bloqueo de la señalización de diversas citoquinas relevantes en esta dermatosis, compleja patogénicamente y con una expresión fenotípica heterogénea, a través de los inhibidores de JAK, ha supuesto una revolución en el tratamiento de la DA. The JAK/STAT (Janus kinase/signal transducer and activator of transcription) pathway is an essential final step in the signaling process of most interleukins with a critical role in the pathogenesis of atopic dermatitis. By achieving broad, intermittent inhibition of the activity of multiple cytokines, JAK inhibitors help modulate T helper 2 cell–mediated inflammation, epidermal barrier dysfunction, and itch signaling. This comprehensive blockade, however, can result in a wider range of adverse effects. We review a number of JAK inhibitors that have been recently approved for use in atopic dermatitis, such as baricitinib, upadacitinib, and abrocitinib, as well as others that are currently in the pipeline or under development, such as gusacitinib, delgocitinib, ruxolitinib, brepocitinib, tofacitinib, and cerdulatinib. The use of JAK inhibitors to block the signaling of numerous cytokines with a critical role in the pathogenesis of atopic dermatitis has revolutionized the treatment of this pathogenically complex, phenotypically heterogeneous skin disease." @default.
• W4384207941 created "2023-07-14" @default.
• W4384207941 creator A5065131106 @default.
• W4384207941 creator A5069598166 @default.
• W4384207941 date "2023-09-01" @default.
• W4384207941 modified "2023-10-15" @default.
• W4384207941 title "Inhibidores de JAK en dermatitis atópica, nuevas perspectivas" @default.
• W4384207941 cites W114839291 @default.
• W4384207941 cites W1836238490 @default.
• W4384207941 cites W2051521434 @default.
• W4384207941 cites W2892635078 @default.
• W4384207941 cites W2923152437 @default.
• W4384207941 cites W2932169608 @default.
• W4384207941 cites W2965796930 @default.
• W4384207941 cites W3000133404 @default.
• W4384207941 cites W3002117906 @default.
• W4384207941 cites W3003334583 @default.
• W4384207941 cites W3004398344 @default.
• W4384207941 cites W3010985734 @default.
• W4384207941 cites W3032018657 @default.
• W4384207941 cites W3044651017 @default.
• W4384207941 cites W3089470786 @default.
• W4384207941 cites W3097229464 @default.
• W4384207941 cites W3106529050 @default.
• W4384207941 cites W3124381021 @default.
• W4384207941 cites W3129325639 @default.
• W4384207941 cites W3134137987 @default.
• W4384207941 cites W3134278412 @default.
• W4384207941 cites W3136297743 @default.
• W4384207941 cites W3151427656 @default.
• W4384207941 cites W3161578803 @default.
• W4384207941 cites W3163616100 @default.
• W4384207941 cites W3164705475 @default.
• W4384207941 cites W3169855608 @default.
• W4384207941 cites W3186250111 @default.
• W4384207941 cites W3189956257 @default.
• W4384207941 cites W3193360717 @default.
• W4384207941 cites W3196175031 @default.
• W4384207941 cites W3196275328 @default.
• W4384207941 cites W3196688555 @default.
• W4384207941 cites W3198787715 @default.
• W4384207941 cites W3200437075 @default.
• W4384207941 cites W3211526154 @default.
• W4384207941 cites W3211634059 @default.
• W4384207941 cites W3212711293 @default.
• W4384207941 cites W3214049954 @default.
• W4384207941 cites W3216146155 @default.
• W4384207941 cites W4210528408 @default.
• W4384207941 cites W4210543176 @default.
• W4384207941 cites W4211026773 @default.
• W4384207941 cites W4220945593 @default.
• W4384207941 cites W4221103278 @default.
• W4384207941 cites W4224060947 @default.
• W4384207941 cites W4224099074 @default.
• W4384207941 cites W4226372944 @default.
• W4384207941 cites W4280526209 @default.
• W4384207941 cites W4282931991 @default.
• W4384207941 cites W4285391544 @default.
• W4384207941 cites W4286515998 @default.
• W4384207941 cites W4289637630 @default.
• W4384207941 cites W4292474822 @default.
• W4384207941 cites W4297855218 @default.
• W4384207941 cites W4309929737 @default.
• W4384207941 cites W4310015221 @default.
• W4384207941 cites W4310668861 @default.
• W4384207941 cites W4312094132 @default.
• W4384207941 cites W4317733689 @default.
• W4384207941 cites W4317930699 @default.
• W4384207941 cites W4318197189 @default.
• W4384207941 cites W4318678070 @default.
• W4384207941 cites W4318754795 @default.
• W4384207941 cites W4319759256 @default.
• W4384207941 cites W4319978914 @default.
• W4384207941 cites W4320857894 @default.
• W4384207941 cites W4321478309 @default.
• W4384207941 cites W4321769022 @default.
• W4384207941 cites W4322718994 @default.
• W4384207941 cites W4323653286 @default.
• W4384207941 cites W4324018500 @default.
• W4384207941 cites W4361263483 @default.
• W4384207941 cites W4386251552 @default.
• W4384207941 doi "https://doi.org/10.1016/j.ad.2023.07.006" @default.
• W4384207941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37453538" @default.
• W4384207941 hasPublicationYear "2023" @default.
• W4384207941 type Work @default.
• W4384207941 citedByCount "0" @default.
• W4384207941 crossrefType "journal-article" @default.
• W4384207941 hasAuthorship W4384207941A5065131106 @default.
• W4384207941 hasAuthorship W4384207941A5069598166 @default.
• W4384207941 hasBestOaLocation W43842079411 @default.
• W4384207941 hasConcept C112392421 @default.
• W4384207941 hasConcept C126322002 @default.
• W4384207941 hasConcept C170493617 @default.
• W4384207941 hasConcept C171958077 @default.
• W4384207941 hasConcept C203014093 @default.
• W4384207941 hasConcept C2778329239 @default.
• W4384207941 hasConcept C2778923194 @default.
• W4384207941 hasConcept C62478195 @default.

• next